JF
Insider
James M Frates
Chief Financial OfficerJames M Frates (Chief Financial Officer) filed 3 Form 4 reports in the trailing twelve months (0 purchases, 3 sales), most often in Amylyx Pharmaceuticals, Inc. (AMLX). The largest single filing was $315K of AMLX (9,768 sh × $32.27, as filed), executed Sep 10.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
3
0 buys · 3 sells
Median delay
–
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$585K
shares × price, as filed
Last traded
Sep 10
Filed Sep 14
Median ADV $78.0M across their filed names
Open performance→Volume by month
Buys $0
Sells $585K
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
3 filings
Sector per market data · by filing · past 12 months
Most traded names
AMLXRecent filings
AMLXSALE
Amylyx Pharmaceuticals, Inc.
View filing →
$315K9,768 sh × $32.27
Exec Sep 10
Filed Sep 14 · 4:00 PM ET AMLXSALE Amylyx Pharmaceuticals, Inc. View filing → $115K
7,909 sh × $14.52
Exec Mar 2
Filed Mar 4 · 5:30 PM ET AMLXSALE Amylyx Pharmaceuticals, Inc. View filing → $155K
10,558 sh × $14.65
Exec Sep 30 2025
Filed Oct 2 2025 · 5:30 PM ET AMLXPURCHASE Amylyx Pharmaceuticals, Inc. View filing → –
40,000 sh · price not plausible
Exec Sep 12 2024
Filed Sep 16 2024 · 5:30 PM ET